Amgen (AMGN) Offering Possible 16.96% Return Over the Next 28 Calendar Days

This article was originally published on this site

Amgen’s most recent trend suggests a bullish bias. One trading opportunity on Amgen is a Bull Put Spread using a strike $180.00 short put and a strike $170.00 long put offers a potential 16.96% return on risk over the next 28 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $180.00 by expiration. The full premium credit of $1.45 would be kept by the premium seller. The risk of $8.55 would be incurred if the stock dropped below the $170.00 long put strike price.

The 5-day moving average is moving down which suggests that the short-term momentum for Amgen is bearish and the probability of a decline in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for Amgen is bearish.

The RSI indicator is at 33.3 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


Key Takeaways from Eli Lilly’s (LLY) Q4 Earnings Report
Wed, 13 Feb 2019 20:07:08 +0000
Here are the key takeaways from Eli Lilly’s (LLY) fourth-quarter earnings conference call.

Moat Index: Dramatic Sector Allocation Shift in 2018
Wed, 13 Feb 2019 17:55:08 +0000
What Did 2018 Bring for Moat Stocks?(Continued from Prior Part)VanEck New Year, New Positioning The U.S. Moat Index is reviewed quarterly to ensure the Index is allocated to companies that Morningstar believes possess a sustainable competitive

Merck’s Keytruda Gets FDA Priority Review for Head/Neck Cancer
Tue, 12 Feb 2019 14:12:02 +0000
Merck’s (MRK) supplemental biologics license application for Keytruda receives a priority review from the FDA for the first-line treatment of patients with recurrent/metastatic head and neck cancer.

AbbVie Buys Rights to Novel Immunotherapy for Multiple Myeloma
Tue, 12 Feb 2019 14:11:02 +0000
AbbVie (ABBV) enters a global strategic transaction agreement with privately-held Teneobio to develop and commercialize the latter’s pre-clinical immunotherapy candidate, TNB-383B, as a multiple myeloma treatment.

Sanofi/Regeneron Cut Price of PCSK9 Inhibitor Praluent by 60%
Tue, 12 Feb 2019 13:56:01 +0000
Sanofi (SNY) and Regeneron (REGN) announce a 60% cut in the U.S. list price of their cholesterol lowering drug, Praluent to improve access and affordability of the product.

Be Sociable, Share!

Related Posts